Physician Life Insurance for Partnership Buy-Sell Agreements: Structuring the Funding

TL;DR. Medical partnership buy-sell agreements are common; the life insurance funding layer decides whether a partner's death triggers an orderly buyout or a crisis. Two structures dominate: cross-purchase, where each partner owns policies on the others, and entity-redemption, where the practice owns policies on each partner. They carry materially different tax treatments, particularly on basis step-up for surviving partners. In New York, the Corporate Practice of Medicine doctrine makes a funded buy-sell effectively mandatory on the death trigger because non-physician heirs cannot legally hold a share of the practice.

Most medical-partnership buy-sell agreements we review are either underfunded, funded the wrong way for the partnership's tax posture, or silent on how to refresh the practice valuation that the funding amount depends on. The PwC US Family Business Survey (2023) reports roughly 39% of family businesses without a documented, funded succession plan do not survive the first generational transition, and physician partnerships where the contract exists on paper but the funding mechanism is not aligned show the same pattern. This piece walks through the two dominant structures, the valuation step most agreements skim past, and the policy-ownership decisions that decide whether the death benefit lands where the partners expect.

Cross-purchase vs entity-redemption buy-sell structures

Cross-purchase and entity-redemption are the two baseline structures for funding a medical partnership buy-sell on death, and the choice drives policy count, tax-basis treatment, and administrative load. Roughly 40% of closely held businesses with buy-sell agreements use cross-purchase and 35% use entity redemption, with the balance running hybrid or wait-and-see structures (American College of Trust and Estate Counsel, 2023). The right structure depends on partner count, state law, and tax strategy.

Cross-purchase: each partner owns policies on the others

Each partner personally owns a policy on every other partner and is named beneficiary. On death, surviving partners collect the tax-free death benefit under IRC §101(a) and use the proceeds to buy the deceased partner's interest from the estate. Surviving partners receive a cost-basis step-up equal to the purchase price, lowering capital-gains tax on a later sale.

The structural cost is policy count: N(N-1). Two partners need two policies, three need six, four need twelve. Above three or four partners, a trusteed cross-purchase (one policy per partner held by a trustee for the others) compresses policy count while preserving the step-up, with transfer-for-value considerations to manage.

Entity-redemption: the practice owns policies on each partner

The PC or PLLC owns one policy per partner and is named beneficiary. On death, the practice collects the death benefit and redeems the deceased partner's interest from the estate. Surviving partners' ownership percentages increase proportionally, but their basis does not step up.

Operational advantage: one policy per partner. Trade-off: the lost basis step-up, which matters most on a future sale. For C-corporation professional practices the death benefit can trigger corporate AMT; for S-corporations and partnerships the pass-through treatment is cleaner.

How New York law narrows the choice

New York's Corporate Practice of Medicine doctrine, rooted in Education Law §§6521–6531 and Business Corporation Law §1503, restricts ownership in a medical PC or PLLC to licensed physicians. A deceased partner's non-physician spouse or adult child cannot hold the practice interest, which means the buy-sell must trigger on death and the remaining physician partners must acquire the interest promptly. Either structure satisfies the acquisition requirement, but the funding has to be fully in place at the death event because a delayed buyout is not legally available.

Practice valuation: how the buy-sell amount is set

The life insurance face amount should equal each partner's proportional share of an agreed practice valuation. The most common failure mode is a valuation set at partnership formation and never refreshed. Medical practice valuations typically run 0.5x to 1.0x annual net collections for primary-care practices and 1.0x to 2.0x for specialty and procedure-heavy practices, with variance by geography, payer mix, and ancillary revenue (AMA Physician Practice Valuation Resources, 2023). The agreement should specify method, refresh cadence, and the party responsible for updates.

Four methods are in routine use. Capitalization of earnings discounts projected practice earnings by a capitalization rate reflecting risk and growth; it is the most technically defensible method. A multiple of net collections applies an industry multiple to trailing-twelve-month collections; simpler, but can overstate value for practices with significant non-operating revenue. Book value is generally useful only as a floor. Independent appraisal runs $5,000 to $25,000 depending on practice size.

A partnership that sets the buy-sell amount at formation and never revisits it drifts toward underfunding as the practice grows. A practice worth $2M at formation and $4M five years later with a stale $2M valuation leaves each surviving partner's buyout half-funded, and the gap falls to practice cash flow or a seller-financed note. The standard cadence is a refresh at least every three years; policy face amounts are adjusted at each refresh, and guaranteed insurability riders let the increase happen without new medical underwriting.

Funding: term, permanent, and the split-funded approach

Term is cheaper than permanent; permanent builds cash value but costs three to five times more at comparable face. Term premiums for a healthy 40-year-old run 5 to 15 cents per $1,000 of face on a 20-year level term, while permanent at the same face runs 1 to 2 dollars per $1,000 annually in the early policy years (Society of Actuaries Individual Life Insurance Experience, 2023). That spread drives the split-funded approach.

A 20-year level term on a 40-year-old partner expires at age 60, which is exactly when mortality risk is rising and the need is still live. Renewal term at that age runs several multiples of the original and is frequently declined for health reasons. Permanent coverage remains in force for the partner's lifetime but costs $25,000 to $60,000 per partner per year at middle ages for a $1M face.

The working approach for most medical partnerships is a split: term covers the bulk of the buyout face during active practice years, and a smaller permanent layer of 20% to 40% of total face covers phased retirement and funds the buyout if death occurs between term expiry and a full buy-out-on-retirement trigger. The split keeps annual premium reasonable while eliminating the coverage cliff at 60.

The transfer-for-value trap on restructuring

The death benefit is generally exempt from federal income tax under IRC §101(a), but restructuring between cross-purchase and entity-redemption triggers IRC §101(a)(2) (IRS IRC §101 and Publication 535, 2024). If a policy is transferred for valuable consideration, the death benefit becomes taxable as ordinary income to the recipient beyond consideration paid plus subsequent premiums. Safe harbors cover transfers to the insured, to a partner of the insured, to a partnership in which the insured is a partner, or to a corporation in which the insured is a shareholder or officer. A reassignment between non-partner parties, or from a partnership to an unrelated entity, can cost the practice the entire income-tax exemption. Any restructuring should run through tax counsel before policy ownership changes.

Policy structuring: ownership, beneficiary, and estate-tax inclusion

Who owns the policy, who pays the premium, and who receives the death benefit decide whether proceeds arrive where the buy-sell intends and whether any portion is pulled into the insured partner's taxable estate. IRC §2042 includes the death benefit in the insured's gross estate when the insured holds "incidents of ownership" at death. The 2026 federal estate-tax exemption is approximately $13.99 million per individual (IRS IRC §2042 and estate tax, 2024), and New York imposes its own estate tax with a 2026 basic exclusion of approximately $7.16 million (NY Department of Taxation and Finance, Estate Tax, 2026). For physicians at peak earnings with practice value plus personal assets, estate-tax inclusion is a real consideration on the NY side where the exclusion is lower.

Under cross-purchase, the other partners own the policy on the insured, keeping the insured out of §2042 inclusion. Under entity-redemption, the practice owns the policy, and if the insured is also a majority shareholder or officer with corporate-level control, the IRS can attribute the corporation's incidents of ownership to the insured under §2042(2). Careful corporate structuring or a trusteed arrangement avoids the attribution, but the analysis is fact-specific.

For partners whose estate size approaches the federal or NY exclusion, an irrevocable life insurance trust (ILIT) can own coverage outside the insured's estate. The ILIT owns the policy, receives the death benefit, and uses proceeds either to buy the practice interest (coordinated with the buy-sell) or to provide estate liquidity. The transfer-for-value rule is active when an existing policy is transferred into the trust, so structuring should run through tax counsel.

Where the funding layer earns its keep

A buy-sell without a funded life insurance layer is a contract that assumes surviving partners will find cash on the death event. In a four-partner practice where each interest is worth $1.5M, that means finding $1.5M inside the buy-sell's payment period, which in most agreements runs 30 to 90 days. Practice cash flow cannot absorb that in a quarter; a bank loan that large is rarely available on buy-sell timing; a seller-financed note locks the partners into a 10-to-15-year relationship with the deceased partner's family that the buy-sell was supposed to close. The life insurance layer is what makes the contract executable on the day it matters.

Our life insurance buy-sell agreement guide for medical practices walks through the structuring mechanics in depth, and the own-occupation disability insurance guide for physicians covers the companion personal disability contract that protects the individual partner's income. The student loan protection rider covers the education-debt layer on top of base disability coverage. Residency-stage physicians should read the residency and fellowship insurance checklist before partnership eligibility. Service-level information lives on our personal life insurance overview and personal disability insurance page. The physicians industry page sets the broader NY context. To walk through an existing buy-sell and the funding layer together, schedule a consultation.